We received from TempraMed Technologies Ltd. and we are glad to publish the following press release:
“TempraMed Technologies Ltd. (“TempraMed” or the “Company”) (CSE:VIVI) is pleased to announce a non-brokered private placement (the “Offering”) of up to 3,289,473 units of the Company (each, a “Unit”) at a price of C$0.76 per Unit for aggregate gross proceeds of up to C$2,500,000. Each Unit will consist of one common share of the Company (each, a “Share”) and one Share purchase warrant of the Company (each, a “Warrant”).
Each Warrant will entitle the holder thereof to purchase one additional Share at a price of C$1.00 at any time on or before the date which is 18 months after the closing date of the Offering.
The proposed use of proceeds from the Offering is to fund new inventory, product development, and to scale the sales and marketing division globally, as well as general working capital.
In accordance with applicable securities laws, the Shares, Warrants and any additional Shares issued upon exercise of the Warrants will be subject to a four-month and one day hold period in Canada from the date of closing of the Offering. The Warrants issued to certain of the investors will be subject to a restriction preventing their exercise if such exercise would result in the holder holding over 9.99% of the issued and outstanding Shares of the Company.
Accordingly, it is anticipated that there will be no new insiders as a result of the Offering.
Closing of the Offering is anticipated to occur on or before November 5, 2025 or such other date or dates as may be determined by the Company, subject to the receipt of investor documentation, funds and compliance with the requirements of the Canadian Securities Exchange (“CSE”).
In connection with the Offering, the Company may pay a finder’s fee to certain qualified arm’s length parties a cash finder’s fee equal to 7% of the gross proceeds raised and a number of finder’s shares (“Finder’s Shares”) equal to 7% of the number of Units placed by such finder.
About TempraMed Technologies Ltd. TempraMed is a global leader in innovative, temperature-controlled medication storage solutions.
Founded with the mission to safeguard the effectiveness of life-saving medications, TempraMed develops patented, FDA-registered, space-grade thermal insulation hassle-free devices that work 24/7 for years without charging or external power. With a proven product line including VIVI Cap and VIVI Epi, and a smart technology platform on the horizon, TempraMed enables patients and healthcare providers to confidently manage temperature-sensitive medications anywhere, anytime.
With operations in North America, Europe, and Asia, TempraMed is advancing the future of medication protection and adherence.
Investors interested learning more about TempraMed are encouraged to contact the Company at:
ir@tempramed.com
www.tempramed.com
Ron Nagar
Chief Executive Officer
TempraMed Technologies Ltd.
Investor Contacts:
Julia Becker
Vice President, Capital”.
Care of the redaction
Please follow us also with a like on Instagram, user name: gio.vanni.acerbi
